文献速递心血管胸部MRPET

混合磁共振与氟脱氧葡萄糖正电子发射断层成像诊断活动性心脏结节病

Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2017-06-14

本研究前瞻性纳入25例临床怀疑活动性心脏结节病的患者,行混合心脏磁共振/正电子发射断层成像(延迟钆增强与氟脱氧葡萄糖),按影像模式分为MR+PET+等四组,并以19例健康心肌对照者评估生理性摄取。结果显示最大靶/正常心肌比值在活动性心脏结节病组更高(P<0.001),诊断AUC为0.98,最佳阈值为1.2(Youden指数0.94)。

要点

  • 特征性延迟钆增强与氟脱氧葡萄糖摄取增高精确对齐(MR+PET+)提示活动性心脏结节病。
  • 最大靶/正常心肌比值诊断活动性心脏结节病的AUC为0.98,最佳阈值1.2(Youden指数0.94)。
  • 全局性或弥漫灶性氟脱氧葡萄糖摄取也见于健康心肌对照者,提示可能为生理性心肌摄取。

核心结论

  • 心脏磁共振/正电子发射断层成像对活动性心脏结节病的诊断有很大前景,单次扫描可同时提供损伤模式和疾病活动度的增量信息。

研究设计与样本

  • 前瞻性研究,纳入25例临床怀疑活动性心脏结节病的患者(12例男性,年龄54.9±9.8岁),行混合心脏磁共振/正电子发射断层成像(延迟钆增强评估损伤模式,氟脱氧葡萄糖评估疾病活动度),并以19例健康心肌对照者行氟脱氧葡萄糖正电子发射断层成像评估。

关键影像表现/征象

  • 8例为MR+PET+(特征性延迟钆增强与氟脱氧葡萄糖摄取增高精确对齐),提示活动性心脏结节病。
  • 1例为MR+PET-(有特征性延迟钆增强但无氟脱氧葡萄糖摄取增高),符合非活动性心脏结节病。
  • 8例为MR-PET-(无特征性延迟钆增强也无氟脱氧葡萄糖摄取增高),无心脏结节病影像学证据。
  • 8例为MR-PET+(无特征性延迟钆增强但有氟脱氧葡萄糖摄取增高),其中6例为全局性心肌摄取、2例为弥漫灶性摄取,其Ki值与最大标准化摄取值均高于MR+PET+患者。
  • 对照者中亦观察到全局性(n=9)和弥漫灶性(n=2)氟脱氧葡萄糖摄取,提示生理性心肌摄取。

诊断标准与关键数值

  • 活动性心脏结节病定义为MR+PET+,即特征性延迟钆增强与氟脱氧葡萄糖摄取增高精确对齐。
  • 最大靶/正常心肌比值在活动性心脏结节病组更高(P<0.001),诊断活动性心脏结节病的AUC为0.98,最佳阈值为1.2(Youden指数0.94)。

临床应用与阅片要点

  • 阅片时需将延迟钆增强的位置与氟脱氧葡萄糖摄取增高的位置精确对齐,二者匹配提示活动性心脏结节病。
  • 无特征性延迟钆增强但出现全局性或弥漫灶性氟脱氧葡萄糖摄取时,需考虑生理性心肌摄取的可能。
  • 最大靶/正常心肌比值可作为活动性心脏结节病的定量影像生物标志物,最佳阈值为1.2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: The purpose of this study was to explore the diagnostic usefulness of hybrid cardiac magnetic resonance (CMR) and positron emission tomography (PET) using 18F-fluorodeoxyglucose (FDG) for active cardiac sarcoidosis.

BACKGROUND: Active cardiac sarcoidosis (aCS) is underdiagnosed and has a high mortality.

METHODS: Patients with clinical suspicion of aCS underwent hybrid CMR/PET with late gadolinium enhancement (LGE) and FDG to assess the pattern of injury and disease activity, respectively. Patients were categorized visually as magnetic resonance (MR)+PET+ (characteristic LGE aligning exactly with increased FDG uptake), MR+PET- (characteristic LGE but no increased FDG), MR-PET- (neither characteristic LGE nor increased FDG), and MR-PET+ (increased FDG uptake in absence of characteristic LGE) and further characterized as aCS+ (MR+PET+) or aCS- (MR+PET-, MR-PET-, MR-PET+). FDG uptake was quantified using maximum target-to-normal-myocardium ratio and the net uptake rate (Ki) from dynamic Patlak analysis. Receiver-operating characteristic methods were used to identify imaging biomarkers for aCS. FDG PET was assessed using computed tomography/PET in 19 control subjects with healthy myocardium.

RESULTS: A total of 25 patients (12 males; 54.9 ± 9.8 years of age) were recruited prospectively; 8 were MR+PET+, suggestive of aCS; 1 was MR+PET-, consistent with inactive cardiac sarcoidosis; and 8 were MR-PET-, with no imaging evidence of cardiac sarcoidosis. Eight patients were MR-PET+ (6 with global myocardial FDG uptake, 2 with focal-on-diffuse uptake); they demonstrated distinct Ki values and hyperintense maximum standardized uptake value compared with MR+PET+ patients. Similar hyperintense patterns of global (n = 9) and focal-on-diffuse (n = 2) FDG uptake were also observed in control patients, suggesting physiological myocardial uptake. Maximum target-to-normal-myocardium ratio values were higher in the aCS+ group (p < 0.001), demonstrating an area under the curve of 0.98 on receiver-operating characteristic analysis for the detection of aCS, with an optimal maximum target-to-normal myocardium ratio threshold of 1.2 (Youden index: 0.94).

CONCLUSIONS: CMR/PET imaging holds major promise for the diagnosis of aCS, providing incremental information about both the pattern of injury and disease activity in a single scan. (In Vivo Molecular Imaging [MRI] of Atherothrombotic Lesions; NCT01418313).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Dweck MR, Abgral R, Trivieri MG, et al. Hybrid Magnetic Resonance Imaging and Positron Emission Tomography With Fluorodeoxyglucose to Diagnose Active Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017. PMID: 28624396. doi:10.1016/j.jcmg.2017.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。